JP2020503362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503362A5 JP2020503362A5 JP2019536919A JP2019536919A JP2020503362A5 JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5 JP 2019536919 A JP2019536919 A JP 2019536919A JP 2019536919 A JP2019536919 A JP 2019536919A JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr
- fibrosis
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 238000006467 substitution reaction Methods 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 4
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 4
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 231100000241 scar Toxicity 0.000 claims 4
- 208000032544 Cicatrix Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000037387 scars Effects 0.000 claims 3
- 229940127254 ASK1 inhibitor Drugs 0.000 claims 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 108010018763 Biotin carboxylase Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 229960004378 nintedanib Drugs 0.000 claims 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 101001054659 Homo sapiens Latent-transforming growth factor beta-binding protein 1 Proteins 0.000 claims 1
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 claims 1
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 claims 1
- 101001004913 Homo sapiens Transforming growth factor beta activator LRRC33 Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 102100027000 Latent-transforming growth factor beta-binding protein 1 Human genes 0.000 claims 1
- 102100027020 Latent-transforming growth factor beta-binding protein 3 Human genes 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000009182 Parasitemia Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 1
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 1
- 102100025954 Transforming growth factor beta activator LRRC33 Human genes 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- -1 or JAK inhibitor Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162088A JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443615P | 2017-01-06 | 2017-01-06 | |
| US62/443,615 | 2017-01-06 | ||
| US201762452866P | 2017-01-31 | 2017-01-31 | |
| US62/452,866 | 2017-01-31 | ||
| US201762514417P | 2017-06-02 | 2017-06-02 | |
| US62/514,417 | 2017-06-02 | ||
| US201762529616P | 2017-07-07 | 2017-07-07 | |
| US62/529,616 | 2017-07-07 | ||
| US201762549767P | 2017-08-24 | 2017-08-24 | |
| US62/549,767 | 2017-08-24 | ||
| US201762558311P | 2017-09-13 | 2017-09-13 | |
| US62/558,311 | 2017-09-13 | ||
| US201762585227P | 2017-11-13 | 2017-11-13 | |
| US62/585,227 | 2017-11-13 | ||
| US201762587964P | 2017-11-17 | 2017-11-17 | |
| US62/587,964 | 2017-11-17 | ||
| US201762588626P | 2017-11-20 | 2017-11-20 | |
| US62/588,626 | 2017-11-20 | ||
| PCT/US2018/012601 WO2018129329A1 (en) | 2017-01-06 | 2018-01-05 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162088A Division JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503362A JP2020503362A (ja) | 2020-01-30 |
| JP2020503362A5 true JP2020503362A5 (enExample) | 2021-02-12 |
| JP7157744B2 JP7157744B2 (ja) | 2022-10-20 |
Family
ID=61198888
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536919A Active JP7157744B2 (ja) | 2017-01-06 | 2018-01-05 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2022162088A Pending JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A Pending JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162088A Pending JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A Pending JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180207267A1 (enExample) |
| EP (1) | EP3551658A1 (enExample) |
| JP (3) | JP7157744B2 (enExample) |
| KR (2) | KR20190098255A (enExample) |
| CN (2) | CN117398457A (enExample) |
| AU (2) | AU2018205231A1 (enExample) |
| BR (1) | BR112019013908A2 (enExample) |
| CA (1) | CA3049005A1 (enExample) |
| CL (1) | CL2019001874A1 (enExample) |
| CO (1) | CO2019007298A2 (enExample) |
| CR (1) | CR20190350A (enExample) |
| DO (1) | DOP2019000180A (enExample) |
| IL (2) | IL267790A (enExample) |
| MX (1) | MX2019008197A (enExample) |
| PE (1) | PE20191661A1 (enExample) |
| PH (1) | PH12019501575A1 (enExample) |
| WO (1) | WO2018129329A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| US20180207267A1 (en) * | 2017-01-06 | 2018-07-26 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgfb1 inhibitors and use thereof |
| US12358992B2 (en) | 2017-07-28 | 2025-07-15 | Scholar Rock, Inc. | LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| JP7540994B2 (ja) | 2018-07-11 | 2024-08-27 | スカラー ロック インコーポレイテッド | 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用 |
| US20210340238A1 (en) | 2018-07-11 | 2021-11-04 | Scholar Rock, Inc. | TGFß1 INHIBITORS AND USE THEREOF |
| WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EA202192130A1 (ru) | 2019-01-30 | 2021-12-28 | Сколар Рок, Инк. | Специфичные к ltbp-комплексу ингибиторы tgf и их применение |
| TW202102207A (zh) * | 2019-03-27 | 2021-01-16 | 新加坡商新加坡保健服務集團有限公司 | 對於癌病具有治療意義的生物標記 |
| WO2020206055A1 (en) * | 2019-04-02 | 2020-10-08 | Yale University | Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| SG11202009970VA (en) | 2019-08-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Cross-Species Anti-Latent TGF-Beta 1 Antibodies And Methods Of Use |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| JP2023511255A (ja) * | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | ＴＧＦ－β阻害剤及びその使用 |
| CN115190812A (zh) | 2020-01-11 | 2022-10-14 | 供石公司 | TGFβ抑制剂及其用途 |
| TWI896628B (zh) | 2020-03-26 | 2025-09-11 | 美國凡德貝爾大學 | 針對嚴重急性呼吸症候群冠狀病毒２(SARS-CoV-2)之人單株抗體 |
| WO2021195485A1 (en) * | 2020-03-27 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| CA3177029A1 (en) | 2020-04-27 | 2021-11-04 | Aaron Sato | Variant nucleic acid libraries for coronavirus |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| IL303349A (en) * | 2020-12-02 | 2023-08-01 | Shanghai Henlius Biotech Inc | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| CN114957476A (zh) * | 2021-02-23 | 2022-08-30 | 复旦大学 | 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CN117295717A (zh) | 2021-05-11 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| JP7691522B2 (ja) | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN119255993A (zh) | 2022-03-22 | 2025-01-03 | 奥托泰利克生物公司 | 噻唑衍生物化合物及其用途 |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN117721079B (zh) * | 2024-01-26 | 2025-03-11 | 广东壹加再生医学研究院有限公司 | 一种促进nk细胞抗肿瘤活性的培养基及培养方法 |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JPH11507843A (ja) | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP2386575A3 (en) | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| GB0230202D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| PT3520815T (pt) | 2005-02-08 | 2022-02-02 | Genzyme Corp | Anticorpos contra tgfbeta |
| PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
| AU2012261933B2 (en) * | 2011-06-03 | 2017-06-15 | Xoma Technology Ltd. | Antibodies specific for TGF-beta |
| WO2013068902A1 (en) * | 2011-11-08 | 2013-05-16 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-m-csf antibodies |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| DK2822592T3 (en) * | 2012-03-08 | 2018-10-15 | Ludwig Institute For Cancer Res Limited | TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF |
| CA2911514A1 (en) * | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP3139957A4 (en) * | 2014-05-06 | 2018-04-25 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2016115345A1 (en) * | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, | Treatment of cancer with anti-lap monoclonal antibodies |
| EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| US20180207267A1 (en) * | 2017-01-06 | 2018-07-26 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgfb1 inhibitors and use thereof |
-
2018
- 2018-01-05 US US15/863,564 patent/US20180207267A1/en not_active Abandoned
- 2018-01-05 PE PE2019001372A patent/PE20191661A1/es unknown
- 2018-01-05 CN CN202310792211.2A patent/CN117398457A/zh active Pending
- 2018-01-05 MX MX2019008197A patent/MX2019008197A/es unknown
- 2018-01-05 JP JP2019536919A patent/JP7157744B2/ja active Active
- 2018-01-05 AU AU2018205231A patent/AU2018205231A1/en not_active Abandoned
- 2018-01-05 WO PCT/US2018/012601 patent/WO2018129329A1/en not_active Ceased
- 2018-01-05 CR CR20190350A patent/CR20190350A/es unknown
- 2018-01-05 BR BR112019013908A patent/BR112019013908A2/pt unknown
- 2018-01-05 KR KR1020197022663A patent/KR20190098255A/ko not_active Ceased
- 2018-01-05 CN CN201880015969.2A patent/CN110382530A/zh active Pending
- 2018-01-05 CA CA3049005A patent/CA3049005A1/en active Pending
- 2018-01-05 EP EP18705030.7A patent/EP3551658A1/en active Pending
- 2018-01-05 KR KR1020247030136A patent/KR20240137126A/ko not_active Ceased
-
2019
- 2019-03-22 US US16/361,486 patent/US20190209682A1/en not_active Abandoned
- 2019-07-02 IL IL267790A patent/IL267790A/en unknown
- 2019-07-03 PH PH12019501575A patent/PH12019501575A1/en unknown
- 2019-07-05 CL CL2019001874A patent/CL2019001874A1/es unknown
- 2019-07-05 DO DO2019000180A patent/DOP2019000180A/es unknown
- 2019-07-08 CO CONC2019/0007298A patent/CO2019007298A2/es unknown
-
2022
- 2022-10-07 JP JP2022162088A patent/JP2022188226A/ja active Pending
-
2023
- 2023-07-11 IL IL304416A patent/IL304416A/en unknown
- 2023-08-01 US US18/363,435 patent/US20240016928A1/en active Pending
-
2024
- 2024-10-01 JP JP2024172672A patent/JP2025000891A/ja active Pending
-
2025
- 2025-05-16 AU AU2025203555A patent/AU2025203555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503362A5 (enExample) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JP6100463B2 (ja) | ＴＮＦαを阻害する安定かつ可溶性の抗体 | |
| JP2011504501A5 (enExample) | ||
| JP7434328B2 (ja) | シトルリン化されたヒストン２ａ及び／又は４に結合する抗体 | |
| JP2018108081A5 (enExample) | ||
| CN106103479B (zh) | 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 | |
| JP2019505527A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2008518936A5 (enExample) | ||
| JP2008532557A (ja) | 新規な抗ｐｌｇｆ抗体 | |
| JP2010527356A5 (enExample) | ||
| JP2016536332A5 (enExample) | ||
| JP2017537084A5 (enExample) | ||
| JP2018093875A5 (enExample) | ||
| JP2011518886A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| CN103974976A (zh) | 用于治疗炎性病症的il17c拮抗剂 | |
| JP2017535285A5 (enExample) | ||
| JP2011518857A5 (enExample) | ||
| JP2015518857A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| JP6383665B2 (ja) | ＩＬ‐１β中和ヒトモノクローナル抗体 | |
| CN116059350A (zh) | 使用抗-il-17a/f抗体的治疗方法 |